Efficacy of Fixed-dose Combination of Brinzolamide and Brimonidine in the Treatment of Open-Angle Glaucoma: A Systematic Review

Abstract

Objective: To systematically review the efficacy and safety of Brinzolamide/Brimonidine (BRZ/BRM) in treating open-angle glaucoma (OAG). Subjects and methods: The systematic review was conducted according to the PRISMA guidelines using three databases (Pubmed, Cochrane, and Embase) till January 2024. Results: Two randomized, triple-blind intervention studies were obtained that met the selection criteria. As a result of 3-month treatment, the fixed-dose combination drug of BRZ 10 mg/mL and BRM 2 mg/mL, twice a day, had the same effect in reducing intraocular pressure as the combination of two drugs BRZ 10 mg/mL and BRM 2 mg/mL alone, twice a day (intraocular pressure difference is -0.1 mmHg). In the two intervention and non-intervention groups, there were similarities in common adverse drug reactions and the rate of adverse events leading to treatment discontinuation. Conclusion: Using the combination of BRZ/BRM in the treatment of OAG is efficacious, safe, and could be a more appropriate treatment method than combining the two individual drugs.